Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

687
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
687
Cancer Vaccines01:30

Cancer Vaccines

531
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
531
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Return to Driving in Patients With Acquired Brain Injury: A Systematic Review With Meta-Analysis.

Occupational therapy international·2026
Same author

Review: structural determinants of organic dyes for controlling biological clearance pathways.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2026
Same author

Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products.

The AAPS journal·2026
Same author

Nanocarriers for the delivery of the CRISPR/Cas9 system.

Nanomedicine (London, England)·2025
Same author

Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T-Cell Enhancement in Immunocompetent HLA-Transgenic Mice.

Allergy·2025
Same author

Solcumin™: a functional hybrid particle with potent anti-inflammatory and antioxidant activities and enhanced storage stability.

Pharmacological reports : PR·2025
Same journal

Mechanistic constraints in dengue severity: a systematic review with evidence stratification and agent-based evaluation of logical sufficiency.

Frontiers in immunology·2026
Same journal

Circadian control of immune homeostasis in cardiovascular health and disease.

Frontiers in immunology·2026
Same journal

An IHC-derived TLS-CD8-macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC.

Frontiers in immunology·2026
Same journal

AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation.

Frontiers in immunology·2026
Same journal

Restoring immune homeostasis in the spinal microenvironment: targeting mechano-inflammation and immunometabolic reprogramming.

Frontiers in immunology·2026
Same journal

A self-perpetuating neuron-intrinsic GSDMD-mtDNA-AIM2 inflammasome axis drives neuronal pyroptosis and cognitive impairment after traumatic brain injury.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: Sep 25, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.

Karin M Knudson1, SuJin Hwang1, Mondona S McCann1

  • 1Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.

Frontiers in Immunology
|April 25, 2022
PubMed
Summary
This summary is machine-generated.

Interleukin-13 receptor alpha-2 (IL-13Rα2) is overexpressed in many solid tumors and promotes cancer progression. Targeting IL-13Rα2 with immunotherapies like CAR T cells shows promise for improving cancer treatment efficacy.

Keywords:
CAR (chimeric antigen receptor) T cellsIL-13Rα2gliobastoma (GBM)immunotoxininterleukin 13 receptor α2

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K

Related Experiment Videos

Last Updated: Sep 25, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) is a high-affinity receptor for the anti-inflammatory cytokine IL-13.
  • IL-13Rα2 is overexpressed in various solid tumors, including glioblastoma, colorectal, adrenocortical, pancreatic, and breast cancers, correlating with poor prognosis.
  • Contrary to previous hypotheses, IL-13 can signal through IL-13Rα2 in human cells, promoting tumor proliferation, survival, invasion, and metastasis.

Purpose of the Study:

  • To review recent developments in IL-13Rα2-targeted cancer therapies.
  • To discuss strategies for enhancing the efficacy of IL-13Rα2-directed cancer treatments.

Main Methods:

  • Review of pre-clinical and clinical studies on IL-13Rα2-targeted therapies.
  • Analysis of emerging therapeutic strategies including immunotoxins, cancer vaccines, and chimeric antigen receptor (CAR) T cells.

Main Results:

  • IL-13Rα2 is a viable immunotherapy target due to its differential expression in tumor versus normal tissues.
  • Multiple therapeutic strategies targeting IL-13Rα2 have shown promise in pre-clinical and clinical studies.
  • IL-13Rα2-mediated signaling contributes to tumor progression and metastasis.

Conclusions:

  • IL-13Rα2 represents an attractive target for cancer immunotherapy.
  • Further research into IL-13Rα2-targeted therapies may lead to improved cancer treatment outcomes.
  • Strategies to enhance IL-13Rα2-directed treatment efficacy are under active investigation.